Indian drugmaker Dr Reddy’s Laboratories has isolated all data center services and shut down key plants globally following a cyberattack.
The move is a preventative measure due to a breach at its servers, first reported by ET Now.
“We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident,” Dr Reddy’s Chief Information Officer Mukesh Rathi said in a statement.
Its plants in the United States, United Kingdom, Brazil, India and Russia are said to be impacted.
Shares of the No.2 drugmaker in India, which has a partnership to run clinical trials of Russia’s Sputnik-V COVID-19 vaccine in India, fell by as much as 4.3% after the news was reported.
Dr Reddy’s received approval to conduct human clinical trials in India together with Russia’s sovereign wealth fund. The Russian Direct Investment Fund will supply 100 million doses of the vaccine to Dr. Reddy’s upon receiving regulatory approval in India.
Hyderabad-based Dr Reddy’s also has tie ups with global firms to sell coronavirus treatments Remdesivir and Favipiravir in India.